Co-Director, Pediatric Stroke Services, Director, MGH Retinoblastoma Program, Director, Mass General Comprehensive Hemophilia Treatment Center, Director, Cardiovascular Thrombosis Laboratory, Member, MGH Blood Transfusion Committee, Member, MGH Thrombosis Committee
Dr. Grabowski is a pediatric hematologist/oncologist with interests in clinical hemostasis and thrombosis (including hemophilia and congenial and acquired bleeding disorders), venous and arterial thrombosis in children and adolescents, eye tumors in children (retinoblastoma), and general pediatric hematology/oncology.  He has additional training in cardiovascular physiology, laboratory coagulation, and biomedical engineering (doctorate in engineering science:  biofluid mechanics and physiologic blood flow.  He is Director of the MGH Comprehensive Hemophilia Treatment Center, Co-Director of the Pediatric Stroke Services and Director of the Cardiovascular Thrombosis Laboratory.  His medical degree is from Mayo Medical School, while his doctorate is from Columbia University.  He has completed fellowships in cardiovascular physiology and biophysics at the Mayo Graduate School of Medicine, and in pediatric hematology/oncology at New York Presbyterian-Weil Cornell Medical Center and Memorial-Sloan Kettering Cancer Center, New York, NY.    He is an Assoc. Prof. of Pediatrics at Harvard Medical School.
He is the Founding President of the Thrombosis and Hemostasis Societies of North America (THSNA), and also Chair and/or member of several national and international Boards and Committees.  These include the Board of THSNA  the Board of the National Blood Clot Alliance Chair of the Mentored Research Program and Chair of the Scientific Review Committee of the Hemostasis and Thrombosis Society of North America member of the Data Safety Monitoring Board of the NHLBI for clinical trials in hemostasis and thrombosis member of the International Data Safety Monitoring Board for emicizumab (new bispecific antibody treatment for hemophiliacs with high-titer inhibitors to either factor VIII or factor IX) and member of the Scientific Advisory Boards for CSL Behring, Octapharma, and Emergent Biosolutions.
55 Fruit Street
Boston, MA 02114-2696